Takeaway

• Saracatinib in combination with docetaxel failed to benefit patients with metastatic, castration-resistant prostate cancer (mCRPC) in a phase 1/2 trial. 
• In light of the negative findings, the investigators do not recommend proceeding to a phase 3 trial.

Why this matters

• Preclinical data suggested a synergistic effect of an Src...